Novogenia AG, an international healthcare company specializing in human genetics and personalized products, announced the U.S. market launch of its new MGT Plus methylation test. The launch, conducted in collaboration with U.S. partner 10X Health, strengthens their joint product pipeline and international collaboration in genetic analysis and longevity.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions, including the processing of vitamins and neurotransmitters. While standard tests analyze only a limited number of genes, MGT Plus covers 27 genes, providing a more comprehensive view of methylation across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health.
“With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes,” said Dr. Daniel Wallerstorfer, CEO of Novogenia AG. “The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways, creating new opportunities for more personalized prevention and health strategies.”
The global direct-to-consumer testing market is growing rapidly. In 2025, the market size reached approximately $4.7 billion and is projected to expand to over $16.0 billion by 2033. Genetic testing represents the largest segment, comprising over 40% of the market, with North America accounting for about 50% of global volume in 2025. This growth is driven by increasing consumer interest in personalized health information and prevention.
For Novogenia, the U.S. launch represents a significant step in internationalizing its product portfolio and capitalizing on the booming genetic testing market. By offering a more detailed analysis, the company aims to differentiate itself in a competitive landscape, potentially influencing how consumers and healthcare providers approach preventive health.
The expanded test could have substantial implications for personalized medicine, allowing for more tailored nutritional and lifestyle recommendations based on individual genetic profiles. For healthcare professionals, MGT Plus offers a tool to better understand patients’ biochemical pathways, potentially improving outcomes in areas like metabolic health and stress management.
Novogenia’s collaboration with 10X Health underscores a broader trend of partnerships between European biotech firms and U.S. distribution networks, facilitating cross-border innovation. As the market for direct-to-consumer genetic testing grows, Novogenia’s move positions it to capture a larger share, particularly in North America where demand is highest.
With the launch of MGT Plus, Novogenia continues to expand its international footprint, offering consumers and practitioners a more comprehensive genetic analysis tool. The company’s commitment to scientific innovation and personalized health strategies is evident in this latest product, which may set new standards in methylation testing.
